On December 2, 2024, Novocure announced positive results from the Phase 3 PANOVA-3 trial, which evaluated Tumor Treating Fields (TTFields) therapy in combination with gemcitabine and nab-paclitaxel for unresectable, locally advanced pancreatic cancer. The trial demonstrated a statistically significant improvement in overall survival (OS), offering a new potential option for this challenging patient population. However, the findings prompt important questions regarding its clinical implementation, quality of life implications, and the broader treatment landscape.
What is Tumor Treating Fields Therapy?
Tumor Treating Fields (TTFields) therapy is a new cancer treatment that uses gentle, low-level electric fields to stop cancer cells from growing and dividing. These electric fields are carefully designed to target fast-growing cancer cells without harming normal cells, which don’t divide as quickly. The treatment is delivered through small patches placed on the skin near the tumor, connected to a portable device that patients can carry with them. TTFields therapy is already used for certain cancers like brain tumors and mesothelioma and is now being studied for other hard-to-treat cancers, such as pancreatic cancer, to see if it can work alongside chemotherapy and other treatments to improve outcomes.
Key Findings from PANOVA-3
The PANOVA-3 trial enrolled 571 patients randomized to receive either:
- Gemcitabine and nab-paclitaxel with TTFields therapy, or
- Gemcitabine and nab-paclitaxel alone.
Results
- Median Overall Survival (mOS):
- TTFields arm: 16.2 months
- Control arm: 14.2 months
- Hazard Ratio (HR): 0.819 (p=0.039)
- Median Progression-Free Survival (mPFS):
- TTFields arm showed a 2-month improvement over control, although exact mPFS values were not specified in the release.
- 12- and 24-Month Survival Rates:
- 13% improvement at 12 months and 33% improvement at 24 months for TTFields.
The safety profile was consistent with previous studies, and TTFields therapy was well tolerated.
Concerns and Considerations
1. The Chemotherapy Backbone
The study utilized gemcitabine and nab-paclitaxel as the chemotherapy backbone, which, while effective, is not the preferred first-line choice for many oncologists managing pancreatic cancer. Trials like NAPOLI-3 have established FOLFIRINOX as the more efficacious regimen, making the choice of chemotherapy in PANOVA-3 a subject of debate. Would the inclusion of TTFields alongside FOLFIRINOX offer better outcomes? Or would increased toxicity outweigh the benefits?
2. Quality of Life with TTFields
While the survival benefits are statistically significant, patients using TTFields must wear a device continuously for prolonged periods. This raises questions about:
- Patient Comfort: How does wearing the device affect daily life?
- Emotional and Physical Burden: Does the device interfere with mobility or cause discomfort?
- Patient Compliance: How feasible is long-term adherence to the device in a real-world setting?
The two-month improvement in mPFS, while meaningful, must be weighed against potential quality-of-life trade-offs.
3. Potential for Conversion to Resectable Disease
An important unanswered question is whether the use of TTFields in locally advanced pancreatic cancer increased the percentage of patients eligible for surgical resection. Surgery remains the only potentially curative option for pancreatic cancer, and a therapy that improves resectability rates would represent a significant advancement.
Implications for Clinical Practice
For Oncologists:
- Patient Selection: Identifying patients who would benefit most from TTFields is critical, especially given the chemotherapy backbone and device requirements.
- Discussion of Trade-Offs: Conversations around the balance of survival benefits versus quality-of-life impacts will be essential.
For Patients:
- Informed Decision-Making: Patients should be educated about the benefits and challenges of TTFields, including survival data, potential side effects, and lifestyle adjustments.
For Researchers:
- Exploration of FOLFIRINOX with TTFields: Future trials incorporating more effective chemotherapy backbones like FOLFIRINOX are needed.
- Resectability Data: Further analysis on whether TTFields increases surgical conversion rates could expand its utility.
Looking Ahead
The PANOVA-3 trial represents a promising step forward in the treatment of locally advanced pancreatic cancer, a historically difficult-to-treat population. While the survival benefits are meaningful, open questions about quality of life, chemotherapy selection, and surgical conversion rates remain. Full results, including secondary endpoints, will provide critical context for integrating TTFields into standard practice.
As we await regulatory decisions and additional data, PANOVA-3 serves as a reminder of the ongoing innovation in pancreatic cancer treatment—a field where even incremental progress can have a significant impact on patient outcomes.
Stay tuned to MedOncMD.com for updates on this evolving story and other breakthroughs in oncology care.
About the author
Dr. Sajeve Thomas is a distinguished medical professional and a compassionate guide in the field of oncology. With over a decade of dedicated experience as a board-certified medical oncologist/internal medicine specialist, Dr. Thomas has become a trusted expert in the treatment of melanoma, sarcoma, and gastrointestinal conditions. He brings a wealth of expertise to the complex and challenging world of oncology.